RP1

Right to Try Law Fails Patients Despite FDA Rejection of RP1 Melanoma Therapy

The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...